Skip to main content
. 2020 Jun 3;15(6):e0233595. doi: 10.1371/journal.pone.0233595

Fig 7. Mean change in visual acuity, baseline visual acuity, and average injection numbers across various regions (primary treated eye set).

Fig 7

The primary treated eye set included all primary treated eyes in patients included in the safety set. Top recruiting countries (treatment-naïve DME) with highest evaluable baseline and year 1 data. For the 1-year time period, all patients with non-missing baseline VA and year 1 VA performed anywhere between Day 319 and Day 409 but who had been in the study for at least 365 days from baseline to last follow-up date were included in the analysis. DME, diabetic macular edema; ETDRS, Early Treatment Diabetic Retinopathy Study; VA, visual acuity.